Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females

Yokomine,Masato; Matsueda,Satoko; Kawano,Kouichiro; Sasada,Tetsuro; Fukui,Akimasa; Yamashita,Takuto; Komatsu,Nobukazu; Shichijo,Shigeki; Tasaki,Kazuto; Matsukuma,Ken; Itoh,Kyogo; Kamura,Toshiharu; Ushijima,Kimio

doi:10.3892/etm.2017.4150

Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females

Authors:
- Masato Yokomine
- Satoko Matsueda
- Kouichiro Kawano
- Tetsuro Sasada
- Akimasa Fukui
- Takuto Yamashita
- Nobukazu Komatsu
- Shigeki Shichijo
- Kazuto Tasaki
- Ken Matsukuma
- Kyogo Itoh
- Toshiharu Kamura
- Kimio Ushijima
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Cancer Vaccine Center, Kurume University Medical Center, Kurume, Fukuoka 839‑0863, Japan, Biostatistics Center, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan
Published online on: February 21, 2017 https://doi.org/10.3892/etm.2017.4150
Pages: 1500-1505

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently prophylactic HPV16/18 L1 virus-like particle (VLP) vaccines are employed with great success for the prevention of HPV infection. However, limited information is available regarding the immune responses against human papillomavirus (HPV) 16/18 L1 subsequent to HPV16/18 L1 VLP vaccination, primarily due to the lack of widely used assays for immune monitoring. The aim of the present study was to identify HPV16 L1‑derived B and T cell epitopes for monitoring the immune responses after HPV16/18 L1 VLP vaccination in healthy females. The levels of immunoglobulin G (IgG), IgE, IgA and IgM reactive to HPV16 L1‑derived peptides were measured by multiplex bead suspension assay. Following detailed B cell epitope mapping, T cell responses specific to HPV16 L1‑derived peptides were evaluated by an IFN-γ ELISPOT assay. The levels of IgG, IgM and IgA reactive to 20‑mer peptides (PTPSGSMVTSDAQIFNKPYW) at positions 293‑312 and 300‑319 of HPV16 L1 were significantly increased in the plasma after 2, 7, and 12 months after first vaccination. Detailed epitope mapping identified the amino acid sequence (TSDAQIFNKP) at position 301‑310 of HPV16 L1 as an immunogenic B cell epitope. In addition, T cell responses to an HLA‑A2‑ and HLA‑A24‑restricted epitope (QIFNKPYWL) at position 305‑313 of HPV16 L1 were increased following immunization, suggesting that the HPV16/18 L1‑VLP vaccination as able to induce specific immune responses in T and B cells simultaneously. The identified B and T cell epitopes may be useful as a biomarker for monitoring the immune responses subsequent to HPV16/18 L1 VLP vaccination. Thus, the present study may provide novel information to improve the understanding of the immune responses to HPV16 L1.

View Figures

View References

1	International Agency for Research on Cancer, . 2012 Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx27–November;2016.
2	Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ: International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518–527. 2003. View Article : Google Scholar : PubMed/NCBI
3	Li N, Franceschi S, Howell-Jones R, Snijders PJ and Clifford GM: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 128:927–935. 2010. View Article : Google Scholar
4	Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN and Thun MJ: Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 97:3133–3275. 2003. View Article : Google Scholar : PubMed/NCBI
5	Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271–278. 2005. View Article : Google Scholar : PubMed/NCBI
6	Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 364:1757–1765. 2004. View Article : Google Scholar : PubMed/NCBI
7	Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 356:1928–1943. 2007. View Article : Google Scholar : PubMed/NCBI
8	Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 374:301–314. 2009. View Article : Google Scholar : PubMed/NCBI
9	Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B and Descamps D: Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Hum Vaccin Immunother. 8:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
10	Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS and Koutsky LA: Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol. 53:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
11	Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iverson OE, Hernandez-Ailta M, Perez G, Brown DR, Koutsky LA, Tay EH, et al: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 26:6844–6851. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ryding J, Dahlberg L, Wallen-Ohman M and Dilner J: Deletion of a major epitope of human papillomavirus tyle16 virus-like particles. J Gen Virol. 88:792–802. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR and Schiller JT: A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 86:494–499. 1994. View Article : Google Scholar : PubMed/NCBI
14	Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kjaer S Kruger, Lowy DR and Schiller JT: Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 321:205–216. 2004. View Article : Google Scholar : PubMed/NCBI
15	Dias D, Van Doren JV, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al: Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 12:959–969. 2005.PubMed/NCBI
16	Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF and Pawlita M: Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem. 51:1845–1853. 2005. View Article : Google Scholar : PubMed/NCBI
17	Fukui A, Matsueda S, Kawano K, Tsuda N, Komatsu N, Shichijo S, Sasada T, Hattori S, Ushijima K, Itoh K and Kamura T: Identification of B cell epitopes reactive to human papillomavirus type-16 L1-derived peptides. Virol J. 9:1992012. View Article : Google Scholar : PubMed/NCBI
18	Komatsu N, Shichijo S, Nakagawa M and Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: A novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest. 64:535–546. 2004. View Article : Google Scholar : PubMed/NCBI
19	Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN and Wolchok JD: Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One. 5:e126702010. View Article : Google Scholar : PubMed/NCBI
20	Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y and Yi Q: CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother. 6:561–571. 2012. View Article : Google Scholar
21	Cubillos C, de la Torre BG, Bárcena J, Andreu D, Sobrino F and Blanco E: Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site. Virol J. 9:662012. View Article : Google Scholar : PubMed/NCBI